Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET

被引:41
|
作者
Paudyal, Pramila [1 ,2 ]
Paudyal, Bishnuhari [1 ,2 ]
Hanaoka, Hirofumi
Oriuchi, Noboru [1 ,2 ]
Iida, Yashuhiko
Yoshioka, Hiroki [1 ,2 ]
Tominaga, Hideyuki [1 ,2 ]
Watanabe, Satoshi [3 ]
Watanabe, Shigeki [3 ]
Ishioka, Noriko S. [3 ]
Endo, Keigo [1 ,2 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol, Maebashi, Gunma, Japan
[2] Gunma Univ, Grad Sch Med, Dept Nucl Med, Maebashi, Gunma, Japan
[3] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Takasaki, Gunma, Japan
关键词
PHASE-II TRIAL; BREAST-CANCER; ANTIBODY; GEMCITABINE; CISPLATIN; MICE;
D O I
10.1111/j.1349-7006.2010.01480.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of 64 Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Trastuzumab was conjugated with the bifunctional chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) and radiolabeled with Cu-64. The molecular specificity of DOTA-trastuzumab was determined in NSCLC cell lines with Her2/neu overexpression (NCI-H2170) and negative expression (NCI-H520). Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with 64 Cu-DOTA-trastuzumab PET and 64 Cu-DOTA-IgG. In vitro studies revealed specific binding of DOTA-trastuzumab in the Her2/neu positive NCI-H2170 cells, while no binding was seen in the Her2/neu negative NCI-H520 cell line. Biodistribution and PET studies revealed a significantly high accumulation of 64 CuDOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 and 48 h post-injection (21.4 +/- 1.4% and 23.2 +/- 5.1% injection dose/gram (% ID/g), respectively). PET imaging of Her2/neu negative NCI-H520 tumors showed much less uptake of 64 CuDOTA- trastuzumab (4.0% ID/g). The NCI-H2170 tumor uptake of 64 Cu-DOTA-trastuzumab was significantly higher than that of 64 Cu-DOTA-IgG (P < 0.0001). 64 Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy. (Cancer Sci 2010; 101: 1045-1050)
引用
收藏
页码:1045 / 1050
页数:6
相关论文
共 50 条
  • [41] The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
    Nagasaka, Misako
    Singh, Vijendra
    Baca, Yasmine
    Sukari, Ammar
    Kim, Chul
    Mamdani, Hirva
    Spira, Alexander, I
    Uprety, Dipesh
    Bepler, Gerold
    Kim, Edward S.
    Raez, Luis E.
    Pai, Sachin Gopalkrishna
    Ikpeazu, Chukwuemeka
    Oberley, Matthew
    Feldman, Rebecca
    Xiu, Joanne
    Korn, W. Michael
    Wozniak, Antoinette J.
    Borghaei, Hossein
    Liu, Stephen, V
    CLINICAL LUNG CANCER, 2022, 23 (01) : 52 - 59
  • [42] Imaging of CDH17-positive gastric cancer xenografts with 64Cu-labeled anti-CDH17 IgG PET
    Fujiwara, K.
    Koyama, K.
    Suga, K.
    Takahashi, M.
    Kusano-Arai, O.
    Mitsui, K.
    Akiba, H.
    Iwanari, H.
    Tsumoto, K.
    Hamakubo, T.
    Momose, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S420 - S420
  • [43] CT and PET imaging in non-small cell lung cancer
    Knoepp, UW
    Ravenel, JG
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 58 (01) : 15 - 30
  • [44] Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay
    Liu, Matthew
    Vathiotis, Ioannis
    Robbins, Charles J.
    Chan, Nay Nwe Nyein
    Moutafi, Myrto
    Burela, Sneha
    Xirou, Vasiliki
    Schalper, Kurt A.
    Herbst, Roy S.
    Syrigos, Konstantinos
    Rimm, David L.
    MODERN PATHOLOGY, 2024, 37 (09)
  • [46] Phamacodynamic Immuno-PET imaging of HSP90 inhibitor on HER2 expression with 64Cu-NOTA-Trastuzumab
    Lee, T.
    Hwang, Y.
    Jeong, I.
    Kim, K.
    Lee, Y.
    Kang, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S686 - S686
  • [47] HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation
    Suzuki, Mikiko
    Shiraishi, Kouya
    Yoshida, Akihiko
    Shirnada, Yoko
    Suzuki, Kenji
    Asamura, Hisao
    Furuta, Koh
    Kohno, Takashi
    Tsuta, Koji
    LUNG CANCER, 2015, 87 (01) : 14 - 22
  • [48] HER-2/NEU and ERCC1 in advanced non-small cell lung cancer
    Yoo, J.
    HISTOPATHOLOGY, 2010, 57 : 220 - 220
  • [49] P53 Her2/neu as prognostic factors in advanced non-small cell lung cancer (NSCLC) treated with paclitaxel
    Yumuk, R
    Turhal, N
    Ahiskali, R
    Gumus, M
    Hatabay, N
    Turken, O
    Ozkan, A
    Salepci, T
    Aliustaoglu, M
    LUNG CANCER, 2005, 49 : S152 - S152
  • [50] Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu
    Ren, Xin-Ling
    Xu, Yan-Ming
    Bao, Wei
    Fu, Hai-Jing
    Wu, Chang-Gui
    Zhao, Ying
    Li, Zhi-Kui
    Zhang, Jian
    Li, Sheng-Qing
    Chen, Wei-Qiang
    Wang, Tao
    Zhang, Rui
    Zhang, Li-Hong
    Qian, Gui-Sheng
    Chen, Si-Yi
    Jia, Lin-Tao
    Yang, An-Gang
    CANCER LETTERS, 2009, 281 (02) : 134 - 143